Characteristics of Neisseria meningitidis isolates causing fatal disease

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 9, 2008, Pages 734-744

  Jacobsson, Susanne ^a   Olcén, Per ^a   Löfdahl, Margareta ^b   Fredlund, Hans ^a   Mölling, Paula ^a  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PENICILLIN G; SULFONAMIDE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL IMMUNITY; BACTERIUM ISOLATE; CHILD; CONTROLLED STUDY; EPIDEMIOLOGICAL DATA; FATALITY; FEMALE; GENDER; GENETIC VARIABILITY; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; MORTALITY; MULTILOCUS SEQUENCE TYPING; NEISSERIA MENINGITIDIS; NONHUMAN; RISK REDUCTION; SEROTYPE; SWEDEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEISSERIA MENINGITIDIS; POPULATION SURVEILLANCE; SEQUENCE ANALYSIS, DNA; SEROTYPING; SWEDEN; YOUNG ADULT;

EID: 50549089019     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540802029565     Document Type: Article

References (32)

1. Peltola, H. (1983) Meningococcal disease-still with us. Rev Infect Dis, 5, pp. 71-91.
2. Stephens, DS, Greenwood, B. and Brandtzaeg, P. (2007) Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet, 369, pp. 2196-2210.
3. van Deuren, M., Brandtzaeg, P. and van der Meer, JW. (2000) Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev, 13, pp. 144-166.
4. Steven, N. and Wood, M. (1995) The clinical spectrum of meningococcal disease, for the age group 15-19 y. Meningococcal disease, pp. 177-205. Wiley, Chichester
5. Vogel, U. and Claus, H. (2003) Molecular epidemiology of Neisseria meningitidis. Front Biosci, 8, pp. 14-22.
6. Vienne, P., Ducos-Galand, M., Guiyoule, A., Pires, R., Giorgini, D. Taha, M-K et al. (2003) The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis, 37, pp. 1639-1642.
7. Massari, P., Ram, S., Macleod, H. and Wetzler, LM. (2003) The role of porins in neisserial pathogenesis and immunity. Trends Microbiol, 11, pp. 87-93.
8. Schwartz, B., Moore, PS and Broome, CV. (1989) Global epidemiology of meningococcal disease. Clin Microbiol Rev, 2, pp. 118-124.
9. Domingo, P., Muniz-Diaz, E., Baraldes, MA, Arilla, M., Barquet, N. Pericas, R. et al. (2004) Relevance of genetically determined host factors to the prognosis of meningococcal disease. Eur J Clin Microbiol Infect Dis, 23, pp. 634-637.
10. Emonts, M., Hazelzet, JA, de Groot, R. and Hermans, PWM. (2003) Host genetic determinants of Neisseria meningitidis infections (erratum appears in Lancet Infect Dis 2003;3:815). Lancet Infect Dis, 3, pp. 565-577.
11. Boisier, P., Nicolas, P., Djibo, S., Taha, MK, Jeanne, I. Mainassara, HB et al. (2007) Meningococcal meningitis: Unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis, 44, pp. 657-663.
12. Rosenstein, NE, Perkins, BA, Stephens, DS, Popovic, T. and Hughes, JM. (2001) Meningococcal disease. N Engl J Med, 344, pp. 1378-1388.
13. Bjune, G., Hoiby, EA, Gronnesby, JK, Arnesen, O., Fredriksen, JH Halstensen, A. et al. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet, 338, pp. 1093-1096.
14. Oster, P., Lennon, D., O'Hallahan, J., Mulholland, K., Reid, S. and Martin, D. (2005) MeNZB: A safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine, 23, pp. 2191-2196.
15. Tappero, JW, Lagos, R., Ballesteros, AM, Plikaytis, B., Williams, D. Dykes, J. et al. (1999) Immunogenicity of 2 serogroup B outer membrane protein meningococcal vaccines: A randomized controlled trial in Chile. JAMA, 281, pp. 1520-1527.
16. van Alphen, L. (2005) Multivalent meningococcal B OMV vaccines. Serogroup B meningococcal vaccine meeting Atlanta, GA, USA
17. Zimmer, SM and Stephens, DS. (2006) Serogroup B meningococcal vaccines. Curr Opin Investig Drugs, 7, pp. 733-739.
18. Stephens, DS. (2007) Conquering the meningococcus. FEMS Microbiol Rev, 31, pp. 3-14.
19. Giuliani, MM, Adu-Bobie, J., Comanducci, M., Arico, B., Savino, S. Santini, L. et al. (2006) A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA, 103, pp. 10834-10839.
20. Zhu, D., Zhang, Y., Barniak, V., Bernfield, L., Howell, A. and Zlotnick, G. (2005) Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model. Infect Immun, 73, pp. 6838-6845.
21. Olcen, P., Danielsson, D. and Kjellander, J. (1975) The use of protein A-containing staphylococci sensitized with anti-meningococcal antibodies for grouping Neisseria meningitidis and demonstration of meningococcal antigen in cerebrospinal fluid. Acta Pathol Microbiol Scand, 83, pp. 387-396.
22. Abdillahi, H. and Poolman, JT. (1987) Whole-cell ELISA for typing Neisseria meningitidis with monoclonal antibodies. FEMS Microbiol Lett, 48, pp. 367-371.
23. Molling, P., Unemo, M., Backman, A. and Olcen, P. (2000) Genosubtyping by sequencing group A, B and C meningococci: A tool for epidemiological studies of epidemics, clusters and sporadic cases. Apmis, 108, pp. 509-516.
24. Jacobsson, S., Issa, M., Unemo, M., Backman, A., Molling, P. Sulaiman, N. et al. (2003) Molecular characterization of group A Neisseria meningitidis isolated in Sudan 1985-2001. Apmis, 111, pp. 1060-1066.
25. Olcen, P. and Fredlund, H. (2003) Do we miss cases of meningococcal meningitis/septicaemia?. Epi aktuellt, 2, p. 1.
26. Smith, I., Bjornevik, AT, Augland, IM, Berstad, A., Wentzel-Larsen, T. and Halstensen, A. (2006) Variations in case fatality and fatality risk factors of meningococcal disease in western Norway, 1985-2002. Epidemiol Infect, 134, pp. 103-110.
27. Gottfredsson, M., Diggle, MA, Lawrie, DI, Erlensdottir, H., Hardardottir, H. Kristinsson, KG et al. (2006) Neisseria meningitidis sequence type and risk for death, Iceland. Emerg Infect Dis, 12, pp. 1066-1073.
28. Sharip, A., Sorvillo, F., Redelings, MD, Mascola, L., Wise, M. and Nguyen, DM. (2006) Population-based analysis of meningococcal disease mortality in the United States, 1990-2002. Pediatr Infect Dis J, 25, pp. 191-194.
29. Yazdankhah, SP, Kriz, P., Tzanakaki, G., Kremastinou, J., Kalmusova, J. Musilek, M. et al. (2004) Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway. J Clin Microbiol, 42, pp. 5146-5153.
30. Barr, J. and Danielsson, D. (1971) Septic gonococcal dermatitis. Br Med J, 1, pp. 482-485.
31. Hotopp, JC, Grifantini, R., Kumar, N., Tzeng, YL, Fouts, D. Frigimelica, E. et al. (2006) Comparative genomics of Neisseria meningitidis: Core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology, 152, pp. 3733-3749.
32. Claus, H., Vogel, U., Swiderek, H., Frosch, M. and Schoen, C. (2007) Microarray analyses of meningococcal genome composition and gene regulation: A review of the recent literature. FEMS Microbiol Rev, 31, pp. 43-51.